Autolus Therapeutics (NASDAQ:AUTL) Shares Up 4% - Here's What Happened

Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report)'s stock price was up 4% during trading on Friday . The stock traded as high as $3.18 and last traded at $3.13. Approximately 2,001,397 shares were traded during mid-day trading, an increase of 39% from the average daily volume of 1,438,985 shares. The stock had previously closed at $3.01.

Analyst Upgrades and Downgrades

AUTL has been the topic of several research analyst reports. Needham & Company LLC reiterated a "buy" rating and set a $9.00 price objective on shares of Autolus Therapeutics in a research report on Monday, November 11th. Redburn Atlantic raised Autolus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 price target on the stock in a research report on Friday. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $9.45.

Autolus Therapeutics Stock Performance

The business's 50 day simple moving average is $3.91 and its 200-day simple moving average is $3.99. The company has a market cap of $819.56 million, a price-to-earnings ratio of -2.55 and a beta of 2.04.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.10). During the same quarter in the previous year, the business earned ($0.26) earnings per share. Research analysts expect that Autolus Therapeutics plc will post -0.84 earnings per share for the current year.

Institutional Investors Weigh In On Autolus Therapeutics

Several large investors have recently made changes to their positions in AUTL. ProShare Advisors LLC acquired a new stake in Autolus Therapeutics in the second quarter valued at approximately $43,000. Capstone Investment Advisors LLC acquired a new stake in shares of Autolus Therapeutics in the third quarter worth about $51,000. Daiwa Securities Group Inc. boosted its stake in shares of Autolus Therapeutics by 2,659.7% during the 2nd quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company's stock worth $55,000 after acquiring an additional 15,293 shares in the last quarter. Herbst Group LLC bought a new stake in shares of Autolus Therapeutics during the 3rd quarter worth about $91,000. Finally, Bayesian Capital Management LP acquired a new position in shares of Autolus Therapeutics during the 1st quarter valued at about $100,000. Institutional investors own 72.83% of the company's stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.